Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar

      Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar

      Farhat Nasim7 March 2019 9:30 AM IST
      Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a...
      USFDA approves Spravato, a controversial drug for depression

      USFDA approves Spravato, a controversial drug for depression

      Farhat Nasim7 March 2019 9:15 AM IST
      The FDA approved Spravato, known chemically as esketamine, based on study results that showed patients taking the drug experienced a bigger...
      Glenmark Pharma appoints Alessandro Riva as CEO of its new innovation company

      Glenmark Pharma appoints Alessandro Riva as CEO of its new innovation company

      Farhat Nasim7 March 2019 9:00 AM IST
      Alessandro Riva also worked in companies including Novartis, Rhone-Poulenc Rorer and Aventis, France.New Delhi: Drug major Glenmark Pharmaceuticals...
      Smuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airport

      Smuggling of anti cancer drug in India worth Rs 1.23 crore, Chinese arrested at airport

      Farhat Nasim6 March 2019 1:45 PM IST
      Schedule H drugs are prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs...
      Alembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointment

      Alembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointment

      Farhat Nasim6 March 2019 9:45 AM IST
      The company's JV, Aleor Dermaceuticals Ltd, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug...
      Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets

      Lupin, Natco receives USFDA nod for Imatinib Mesylate tablets

      Farhat Nasim6 March 2019 9:30 AM IST
      Imatinib Mesylate is a generic version of Novartis Pharmaceuticals Corporation's Gleevec tablets in the same strengths, Lupin said in a filing to BSE....
      Zydus Cadila gets USFDA nod to Rivastigmine transdermal system, Rosuvastatin

      Zydus Cadila gets USFDA nod to Rivastigmine transdermal system, Rosuvastatin

      Farhat Nasim6 March 2019 9:15 AM IST
      Rivastigmine transdermal system and Rosuvastatin will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad, Zydus...
      CHMP recommends Sanofi Zynquista for treatment of adults with type 1 diabetes

      CHMP recommends Sanofi Zynquista for treatment of adults with type 1 diabetes

      Farhat Nasim6 March 2019 9:00 AM IST
      Sanofi and Lexicon developed Sotagliflozin is also currently being reviewed by the U.S. Food and Drug Administration (FDA) and has the potential to be...
      Zydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issues

      Zydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issues

      Farhat Nasim5 March 2019 4:52 PM IST
      Doxazosin is used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia, it added. New Delhi: Gujarat based...
      Glenmark Pharma gets USFDA nod for generic version of Micardis HCT tablets

      Glenmark Pharma gets USFDA nod for generic version of Micardis HCT tablets

      Farhat Nasim5 March 2019 10:15 AM IST
      The approved products is a generic version of Boehringer Ingelheim Pharmaceuticals Inc's Micardis HCT tablets. MICARDIS HCT (telmisartan and...
      OxyContin maker Purdue Pharma exploring bankruptcy: Report

      OxyContin maker Purdue Pharma exploring bankruptcy: Report

      Farhat Nasim5 March 2019 9:20 AM IST
      Sales of OxyContin and other opioids have fallen amid public concern about their addictive nature, and as restrictions on opioid prescribing have been...
      Eli Lilly offers generic version of insulin Humalog at half price

      Eli Lilly offers generic version of insulin Humalog at half price

      Farhat Nasim5 March 2019 9:15 AM IST
      The price of Lilly’s Humalog rose from $35 to $234 per dose between 2001 and 2015, a 585 per cent increase, the senators, Republican Chuck Grassley...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok